English | 繁體

Search in the results

UM

Browse/Search Results:  1-10 of 247 Help

Selected(0)Clear Items/Page:    Sort:
Exploring the clinical implications and applications of exosomal miRNAs in gliomas: a comprehensive study Journal article
Yang, Liang, Niu, Zhen, Ma, Zhixuan, Wu, Xiaojie, Vong, Chi Teng, Li, Ge, Feng, Ying. Exploring the clinical implications and applications of exosomal miRNAs in gliomas: a comprehensive study[J]. Cancer Cell International, 2024, 24(1), 323.
Authors:  Yang, Liang;  Niu, Zhen;  Ma, Zhixuan;  Wu, Xiaojie;  Vong, Chi Teng; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0 | Submit date：2024/10/10
Diagnosis  Exosomal Micrornas  Glioma  Prognosis  Treatment  
KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges Review article
2024
Authors:  Li, Chang Yun;  Wang, Wanhe;  Leung, Chung Hang;  Yang, Guan Jun;  Chen, Jiong
Favorite | TC[WOS]:2 TC[Scopus]:2  IF:27.7/31.3 | Submit date：2024/06/05
Breast Cancer  Histone Demethylation  Kdm5  Kdm5 Inhibitors  Therapeutic Target  
Pathogenic variants in human DNA damage repair genes mostly arose in recent human history Journal article
Zhao, Bojin, Li, Jiaheng, Sinha, Siddharth, Qin, Zixin, Kou, Si Hoi, Xiao, Fengxia, Lei, Huijun, Chen, Tianhui, Cao, Wenming, Ding, Xiaofan, Wang, San Ming. Pathogenic variants in human DNA damage repair genes mostly arose in recent human history[J]. BMC Cancer, 2024, 24(1), 415.
Authors:  Zhao, Bojin;  Li, Jiaheng;  Sinha, Siddharth;  Qin, Zixin;  Kou, Si Hoi; et al.
Favorite | TC[WOS]:3 TC[Scopus]:3  IF:3.4/3.8 | Submit date：2024/05/16
Archaeological  Dna Damage Repair  Evolutionary Origin  Pathogenic Variants  Phylogenetic  
Activation of the PERK/eIF2α axis is a pivotal prerequisite of taxanes to cancer cell apoptosis and renders synergism to overcome paclitaxel resistance in breast cancer cells Journal article
Cai, Wanhua, Rong, Dade, Ding, Jiayu, Zhang, Xiaomei, Wang, Yuwei, Fang, Ying, Xiao, Jing, Yang, Shulan, Wang, Haihe. Activation of the PERK/eIF2α axis is a pivotal prerequisite of taxanes to cancer cell apoptosis and renders synergism to overcome paclitaxel resistance in breast cancer cells[J]. Cancer Cell International, 2024, 24(1), 249.
Authors:  Cai, Wanhua;  Rong, Dade;  Ding, Jiayu;  Zhang, Xiaomei;  Wang, Yuwei; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:5.3/5.0 | Submit date：2024/08/05
Breast Cancer  Er Stress  Perk/eif2α  Taxane  Tumor Drug Resistance  
YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment Journal article
Yang, Zhenyun, Wang, Xin, Fu, Yizhen, Wu, Weijie, Hu, Zili, Lin, Qingyang, Peng, Wei, Pan, Yangxun, Wang, Juncheng, Chen, Jinbin, Hu, Dandan, Zhou, Zhongguo, Xu, Li, Zhang, Yaojun, Hou, Jiajie, Chen, Minshan. YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment[J]. Molecular Cancer, 2024, 23(1), 186.
Authors:  Yang, Zhenyun;  Wang, Xin;  Fu, Yizhen;  Wu, Weijie;  Hu, Zili; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:27.7/31.3 | Submit date：2024/10/10
AFP-HSP90 mediated MYC/MET activation promotes tumor progression in hepatocellular carcinoma and gastric cancers Journal article
Lin, Ziqi, Pan, Rulu, Wu, Liyue, Zhu, Fangsheng, Fang, Qiwei, Kwok, Hang Fai, Lu, Xincheng. AFP-HSP90 mediated MYC/MET activation promotes tumor progression in hepatocellular carcinoma and gastric cancers[J]. Cancer Cell International, 2024, 24(1), 283.
Authors:  Lin, Ziqi;  Pan, Rulu;  Wu, Liyue;  Zhu, Fangsheng;  Fang, Qiwei; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:5.3/5.0 | Submit date：2024/09/03
Peptides for microbe-induced cancers: latest therapeutic strategies and their advanced technologies Review article
2024
Authors:  Lin, Ziqi;  Assaraf, Yehuda G.;  Kwok, Hang Fai
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:7.7/10.3 | Submit date：2024/08/05
Anticancer Agents  Microbe- And Virus-induced Cancers  Microbial And Viral Infections  Peptide-based Therapeutics  
KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges Journal article
Chang-Yun Li, Wanhe Wang, Chung-Hang Leung, Guan-Jun Yang, Jiang Chen. KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges[J]. Molecular Cancer, 2024, 23(109), 1975.
Authors:  Chang-Yun Li;  Wanhe Wang;  Chung-Hang Leung;  Guan-Jun Yang;  Jiang Chen
Favorite |   IF:27.7/31.3 | Submit date：2024/08/30
Revealing the secret behind Epstein-Barr virus-specific tumor immune contexture Journal article
Deng, Chu Xia. Revealing the secret behind Epstein-Barr virus-specific tumor immune contexture[J]. Cancer Communications, 2024, 44(4), 491-494.
Authors:  Deng, Chu Xia
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:20.1/16.7 | Submit date：2024/05/02
Characteristics of clinical trials of new oncology drugs approved in China Journal article
Yang, Jing, Yang, Ji, Hu, Yuan Jia. Characteristics of clinical trials of new oncology drugs approved in China[J]. Cancer, 2024, 130(5), 671-682.
Authors:  Yang, Jing;  Yang, Ji;  Hu, Yuan Jia
Favorite | TC[WOS]:1 TC[Scopus]:2  IF:6.1/6.7 | Submit date：2024/05/16
Clinical Evidence  Drug Lag  Novel Anticancer Drugs  Pivotal Clinical Trials  Programmed Death-1 (Pd-1) Inhibitors  Programmed Death-ligand 1 (Pd-l1) Inhibitors